Saturday, 12 September 2009

Glatiramer Acetate




Scheme

USAN

ATC (Anatomical Therapeutic Chemical Classification)

L03AX13

CAS registry number (Chemical Abstracts Service)

0147245-92-9

Chemical Formula

(C23-H41-N5-O11)x·(C2-H4-O2)x

Therapeutic Category

Immunomodulator

Chemical Name

L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)

Foreign Name

  • Glatiramer acetat (German)

Generic Names

  • Glatiramer Acetate (OS: USAN, BAN)
  • 147245-92-9 (IS: CAS, old)
  • COP 1 (IS: Teva)
  • Copolymer 1 (IS)
  • Copolymer I (IS: synthetic peptide)
  • Glat copolymer (IS)
  • Tgal copolymer (IS)

Brand Names

  • Copaxone
    Aventis, Luxembourg; BiosintĂ©tica, Brazil; Dr. Fisher, Netherlands; Elmor, Venezuela; EU-Pharma, Netherlands; Euro, Netherlands; Lemery, Mexico; Med, Turkey; Medco, Peru; Providens, Croatia (Hrvatska); Sanofi-Aventis, Austria; Sanofi-Aventis, Australia; Sanofi-Aventis, Belgium; Sanofi-Aventis, Germany; Sanofi-Aventis, Finland; Sanofi-Aventis, France; Sanofi-Aventis, Georgia; Sanofi-Aventis, Ireland; Sanofi-Aventis, New Zealand; Sanofi-Aventis, Sweden; Sanofi-Aventis - Produtos farmacĂȘuticos, S.A., Portugal; Sanofi-Aventis S.A.U., Spain; Teva, Argentina; Teva, Bulgaria; Teva, Bulgaria; Teva, Czech Republic; Teva, Germany; Teva, Denmark; Teva, Estonia; Teva, Greece; Teva, Hungary; Teva, Israel; Teva, Iceland; Teva, Italy; Teva, Lithuania; Teva, Luxembourg; Teva, Latvia; Teva, Malta; Teva, Netherlands; Teva, Norway; Teva, Romania; Teva, Serbia; Teva, Slovenia; Teva, Slovakia; Teva Neuroscience, Canada; Teva Neuroscience, United States; Teva Pharma, Switzerland; Teva Pharmaceuticals, United Kingdom; Teva Pharmaceuticals, Poland; Teva Pharmaceuticals, South Africa


  • Donecept
    Actavis, Ireland

International Drug Name Search

Glossary

BANBritish Approved Name
CASChemical Abstracts Service
ISInofficial Synonym
OSOfficial Synonym
USANUnited States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

No comments:

Post a Comment